Guzman Sanchez-Schmitz

Guzman Sanchez-Schmitz

Auto-generated profile, based on publicly available information

Guzman Sanchez-Schmitz

Precision Vaccines Program, Division of Infectious Diseases, Boston Children's Hospital, Boston, MA, United States

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2002 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
GRGwendalyn J. Randolph
Gwendalyn J. Randolph
GSGuzman Sanchez-Schmitz
Guzman Sanchez-Schmitz
RLRonald M. Liebman
Ronald M. Liebman
KSKnut SchäkEl
Knut SchäkEl
Much remains to be learned about the physiologic events that promote monocytes to become lymph-homing dendritic cells (DCs). In a model of transendothelial trafficking, some monocytes become DCs in response to endogenous signals. These DCs migrate across endothelium in the ablumenal-to-lumenal direction (reverse transmigration), reminiscent of the migration into lymphatic vessels. Here we show that the subpopulation of monocytes that expresses CD16 (Fcγ receptor III) is predisposed to become migratory DCs. The vast majority of cells derived from CD16+ monocytes reverse transmigrated, and their presence was associated with migratory cells expressing high levels of CD86 and human histocompatibility leukocyte antigen (HLA)-DR, and robust capacity to induce allogeneic T cell proliferation. A minority of CD16− monocytes reverse transmigrated, and these cells stimulated T cell proliferation less efficiently. CD16 was not functionally required for reverse transmigration, but promoted cell survival when yeast particles (zymosan) were present as a maturation stimulus in the subendothelial matrix. The cell surface phenotype and migratory characteristics of CD16+ monocytes were inducible in CD16− monocytes by preincubation with TGFβ1. We propose that CD16+ monocytes may contribute significantly to precursors for DCs that transiently survey tissues and migrate to lymph nodes via afferent lymphatic vessels.

8 November 2004 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
CQChunfeng Qu
Chunfeng Qu
EEEmmerson W. Edwards
Emmerson W. Edwards
FTFrank Tacke
Frank Tacke
VAVérOnique Angeli
VérOnique Angeli
JLJaime Llodrá
Jaime Llodrá
GRGwendalyn J. Randolph
Gwendalyn J. Randolph
Studying the influence of chemokine receptors (CCRs) on monocyte fate may reveal information about which subpopulations of monocytes convert to dendritic cells (DCs) and the migration pathways that they use. First, we examined whether prominent CCRs on different monocyte subsets, CCR2 or CX3CR1, mediated migration events upstream of the accumulation of monocyte-derived DCs in lymph nodes (LNs). Monocytes were labeled and traced by uptake of latex microspheres in skin. Unexpectedly, neither CCR2 nor CX3CR1 were required. However, absence of CCR2 led to an increased labeling of the minor Gr-1int monocyte population, and the number of latex+ DCs that emigrated to LNs was correspondingly increased. Characterization of Gr-1int monocytes revealed that they selectively expressed CCR7 and CCR8 mRNA in blood. CCR7 and CCR8 pathways were used by monocyte-derived DCs during mobilization from skin to LNs. The role of CCR8 in emigration from tissues also applied to human monocyte-derived cells in a model of transendothelial trafficking. Collectively, the data suggest that Gr-1int monocytes may be most disposed to become a lymphatic-migrating DCs. When these monocyte-derived DCs exit skin to emigrate to LNs, they use not only CCR7 but also CCR8, which was not previously recognized to participate in migration to LNs.

12 March 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
ALAmy H. Lee
Amy H. Lee
CSCasey P. Shannon
Casey P. Shannon
NANelly Amenyogbe
Nelly Amenyogbe
Tue Bjerg BennikeTue Bjerg Bennike
Tue Bjerg Bennike
JAJoann Arce
Joann Arce
TKTobias R. Kollmann
Tobias R. Kollmann
Systems biology can unravel complex biology but has not been extensively applied to human newborns, a group highly vulnerable to a wide range of diseases. We optimized methods to extract transcriptomic, proteomic, metabolomic, cytokine/chemokine, and single cell immune phenotyping data from <1 ml of blood, a volume readily obtained from newborns. Indexing to baseline and applying innovative integrative computational methods reveals dramatic changes along a remarkably stable developmental trajectory over the first week of life. This is most evident in changes of interferon and complement pathways, as well as neutrophil-associated signaling. Validated across two independent cohorts of newborns from West Africa and Australasia, a robust and common trajectory emerges, suggesting a purposeful rather than random developmental path. Systems biology and innovative data integration can provide fresh insights into the molecular ontogeny of the first week of life, a dynamic developmental phase that is key for health and disease.

1 December 2001 in International Immunology
Verified
Journal Article
Open access
PDF file
CTCarmen Sánchez Torres
Carmen Sánchez Torres
GGG S García-Romo
G S García-Romo
MCM A Cornejo-Cortés
M A Cornejo-Cortés
ARA Rivas-Carvalho
A Rivas-Carvalho
GSG Sánchez-Schmitz
G Sánchez-Schmitz
Experimental protocols for cancer immunotherapy include the utilization of autologous monocyte-derived dendritic cells (moDC) pulsed with tumor antigens. However, disease can alter the characteristics of monocyte precursors and some patients have increased numbers (up to 40%) of the minor CD16+ monocyte subpopulation, which in healthy individuals represent 10% of blood monocytes. At the present, the capacity of CD16+ monocytes to differentiate into DC has not been evaluated. Here, we investigated the ability of CD16+ monocytes cultured with granulocyte– macrophage colony-stimulating factor, IL-4 and tumor necrosis factor-α to generate DC in vitro, and we compared them to DC derived from regular CD16− monocytes. Both monocyte subsets gave rise to cells with DC characteristics. They internalized soluble and particulate antigens similarly, and both were able to stimulate T cell proliferation in autologous and allogeneic cultures. Nevertheless, CD16+ moDC expressed higher levels of CD86, CD11a and CD11c, and showed lower expression of CD1a and CD32 compared to CD16− moDC. Lipopolysaccharide-stimulated CD16− moDC expressed increased levels of IL-12 p40 mRNA and secreted greater amounts of IL-12 p70 than CD16+ moDC, whereas levels of transforming growth factor-β1 mRNA were higher on CD16+ moDC. Moreover, CD4+ T cells stimulated with CD16+ moDC secreted increased amounts of IL-4 compared to those stimulated by CD16− moDC. These data demonstrate that both moDC are not equivalent, suggesting either that they reach different stages of maturation during the culture or that the starting monocytes belong to cell lineages with distinct differentiation capabilities.

1 November 2017 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Open access
DDDavid J. Dowling
David J. Dowling
ESEvan Scott
Evan Scott
ASAnnette Scheid
Annette Scheid
IBIlana Bergelson
Ilana Bergelson
SJSweta Joshi
Sweta Joshi
OLOfer Levy
Ofer Levy
Newborns display distinct immune responses, leaving them vulnerable to infections and impairing immunization. Targeting newborn dendritic cells (DCs), which integrate vaccine signals into adaptive immune responses, might enable development of age-specific vaccine formulations to overcome suboptimal immunization. Small-molecule imidazoquinoline Toll-like receptor (TLR) 8 agonists robustly activate newborn DCs but can result in reactogenicity when delivered in soluble form. We used rational engineering and age- and species-specific modeling to construct and characterize polymer nanocarriers encapsulating a TLR8 agonist, allowing direct intracellular release after selective uptake by DCs. Chemically similar but morphologically distinct nanocarriers comprised of amphiphilic block copolymers were engineered for targeted uptake by murine DCs in vivo, and a range of TLR8 agonist-encapsulating polymersome formulations were then synthesized. Novel 96-well in vitro assays using neonatal human monocyte-derived DCs and humanized TLR8 mouse bone marrow-derived DCs enabled benchmarking of the TLR8 agonist-encapsulating polymersome formulations against conventional adjuvants and licensed vaccines, including live attenuated BCG vaccine. Immunogenicity of the TLR8 agonist adjuvanted antigen 85B (Ag85B)/peptide 25-loaded BCG-mimicking nanoparticle formulation was evaluated in vivo by using humanized TLR8 neonatal mice. Although alum-adjuvanted vaccines induced modest costimulatory molecule expression, limited TH-polarizing cytokine production, and significant cell death, BCG induced a robust adult-like maturation profile of neonatal DCs. Remarkably, TLR8 agonist polymersomes induced not only newborn DC maturation profiles similar to those induced by BCG but also stronger IL-12p70 production. On subcutaneous injection to neonatal mice, the TLR8 agonist-adjuvanted Ag85B peptide 25 formulation was comparable with BCG in inducing Ag85B-specific CD4+ T-cell numbers. TLR8 agonist-encapsulating polymersomes hold substantial potential for early-life immunization against intracellular pathogens. Overall, our study represents a novel approach for rational design of early-life vaccines.

27 August 2004 in Springer Seminars in Immunopathology
Verified
Journal Article
Closed access
PDF file
GRGwendalyn J. Randolph
Gwendalyn J. Randolph
GSGuzman Sanchez-Schmitz
Guzman Sanchez-Schmitz
VAVeronique Angeli
Veronique Angeli